IL129382A - Method for identifying embryonic cells using antibodies against fetal hemoglobin - Google Patents

Method for identifying embryonic cells using antibodies against fetal hemoglobin

Info

Publication number: IL129382A
Authority: IL; Israel
Prior art keywords: fetal; antibody; cells; hemoglobin; cell
Prior art date: 1996-10-21

Application number

IL12938297A

Other languages

English (en)

Hebrew (he)

Other versions

IL129382A0 (en

Original Assignee

Applied Imaging Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-21

Filing date

1997-10-20

Publication date

2002-09-12

1997-10-20 Application filed by Applied Imaging Inc filed Critical Applied Imaging Inc

1997-10-20 Priority to IL14569197A priority Critical patent/IL145691A/xx

2000-02-17 Publication of IL129382A0 publication Critical patent/IL129382A0/xx

2002-09-12 Publication of IL129382A publication Critical patent/IL129382A/en

Links

230000001605 fetal effect Effects 0.000 title claims abstract description 140
238000000034 method Methods 0.000 title claims abstract description 87
108010054147 Hemoglobins Proteins 0.000 title claims abstract description 45
102000001554 Hemoglobins Human genes 0.000 title claims abstract description 45
230000003135 anti-embryonic effect Effects 0.000 title claims description 11
210000004027 cell Anatomy 0.000 claims abstract description 123
210000004369 blood Anatomy 0.000 claims abstract description 51
239000008280 blood Substances 0.000 claims abstract description 51
210000003924 normoblast Anatomy 0.000 claims abstract description 32
150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
108020004707 nucleic acids Proteins 0.000 claims abstract description 21
102000039446 nucleic acids Human genes 0.000 claims abstract description 21
102000004169 proteins and genes Human genes 0.000 claims abstract description 16
102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 7
108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 7
108091005461 Nucleic proteins Proteins 0.000 claims abstract description 7
210000003743 erythrocyte Anatomy 0.000 claims description 71
239000000523 sample Substances 0.000 claims description 71
230000008774 maternal effect Effects 0.000 claims description 46
239000012634 fragment Substances 0.000 claims description 18
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 14
239000002853 nucleic acid probe Substances 0.000 claims description 14
108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
102100030826 Hemoglobin subunit epsilon Human genes 0.000 claims description 9
108091005879 Hemoglobin subunit epsilon Proteins 0.000 claims description 9
239000003550 marker Substances 0.000 claims description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
239000003298 DNA probe Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
239000007787 solid Substances 0.000 claims description 8
238000000684 flow cytometry Methods 0.000 claims description 7
230000002175 menstrual effect Effects 0.000 claims description 7
108020003215 DNA Probes Proteins 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 5
108090000790 Enzymes Proteins 0.000 claims description 5
239000011324 bead Substances 0.000 claims description 5
230000000890 antigenic effect Effects 0.000 claims description 4
229960002685 biotin Drugs 0.000 claims description 4
235000020958 biotin Nutrition 0.000 claims description 4
239000011616 biotin Substances 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 4
108090001008 Avidin Proteins 0.000 claims description 3
238000010261 blood fractionation Methods 0.000 claims description 3
239000002771 cell marker Substances 0.000 claims description 3
108091005886 Hemoglobin subunit gamma Proteins 0.000 claims description 2
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims description 2
108010090804 Streptavidin Proteins 0.000 claims description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
108020004518 RNA Probes Proteins 0.000 claims 1
239000003391 RNA probe Substances 0.000 claims 1
230000002934 lysing effect Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 23
230000003321 amplification Effects 0.000 abstract description 13
210000003754 fetus Anatomy 0.000 abstract description 13
238000003199 nucleic acid amplification method Methods 0.000 abstract description 13
230000005856 abnormality Effects 0.000 abstract description 5
230000002759 chromosomal effect Effects 0.000 abstract description 3
238000011156 evaluation Methods 0.000 abstract description 2
238000000338 in vitro Methods 0.000 abstract 1
108020004414 DNA Proteins 0.000 description 46
108060003951 Immunoglobulin Proteins 0.000 description 20
102000018358 immunoglobulin Human genes 0.000 description 20
210000000349 chromosome Anatomy 0.000 description 16
239000002609 medium Substances 0.000 description 16
210000000265 leukocyte Anatomy 0.000 description 14
206010018910 Haemolysis Diseases 0.000 description 12
230000000295 complement effect Effects 0.000 description 12
230000008588 hemolysis Effects 0.000 description 12
238000009396 hybridization Methods 0.000 description 12
238000004458 analytical method Methods 0.000 description 10
239000003153 chemical reaction reagent Substances 0.000 description 10
238000003752 polymerase chain reaction Methods 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000005119 centrifugation Methods 0.000 description 8
239000000084 colloidal system Substances 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
229940072221 immunoglobulins Drugs 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
230000005945 translocation Effects 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
108010044495 Fetal Hemoglobin Proteins 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
238000013019 agitation Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
239000000834 fixative Substances 0.000 description 6
239000000499 gel Substances 0.000 description 6
210000003714 granulocyte Anatomy 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
238000007792 addition Methods 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
210000004700 fetal blood Anatomy 0.000 description 5
238000012252 genetic analysis Methods 0.000 description 5
102000018146 globin Human genes 0.000 description 5
108060003196 globin Proteins 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000007901 in situ hybridization Methods 0.000 description 5
238000002955 isolation Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
239000004033 plastic Substances 0.000 description 5
230000035935 pregnancy Effects 0.000 description 5
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 5
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
201000010374 Down Syndrome Diseases 0.000 description 4
206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
206010044688 Trisomy 21 Diseases 0.000 description 4
238000002669 amniocentesis Methods 0.000 description 4
238000000137 annealing Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000000975 dye Substances 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000003793 prenatal diagnosis Methods 0.000 description 4
230000008707 rearrangement Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108020005187 Oligonucleotide Probes Proteins 0.000 description 3
102000007238 Transferrin Receptors Human genes 0.000 description 3
108010033576 Transferrin Receptors Proteins 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
-1 haptens Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
238000007899 nucleic acid hybridization Methods 0.000 description 3
239000002751 oligonucleotide probe Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000013615 primer Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
210000002993 trophoblast Anatomy 0.000 description 3
238000012800 visualization Methods 0.000 description 3
102000003846 Carbonic anhydrases Human genes 0.000 description 2
108090000209 Carbonic anhydrases Proteins 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108700005091 Immunoglobulin Genes Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000037280 Trisomy Diseases 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
210000001766 X chromosome Anatomy 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000151 deposition Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000009877 rendering Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
108020001019 DNA Primers Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
201000003542 Factor VIII deficiency Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010003471 Fetal Proteins Proteins 0.000 description 1
102000004641 Fetal Proteins Human genes 0.000 description 1
208000015872 Gaucher disease Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102100030387 Hemoglobin subunit zeta Human genes 0.000 description 1
108091005905 Hemoglobin subunit zeta Proteins 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010076830 Thionins Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
208000005980 beta thalassemia Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
210000001136 chorion Anatomy 0.000 description 1
210000004252 chorionic villi Anatomy 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000013461 design Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
101150015424 dmd gene Proteins 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
229950005098 ethoxzolamide Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
231100000562 fetal loss Toxicity 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
108010022155 hemoglobin Portland Proteins 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
238000001531 micro-dissection Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
230000035772 mutation Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000010422 painting Methods 0.000 description 1
238000004091 panning Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000020509 sex determination Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001296 transplacental effect Effects 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Dispersion Chemistry (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL12938297A 1996-10-21 1997-10-20 Method for identifying embryonic cells using antibodies against fetal hemoglobin IL129382A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL14569197A IL145691A (en)	1996-10-21	1997-10-20	Method to identify fetal cells using anti-embryonic hemoglobin antibodies

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/734,556 US5731156A (en)	1996-10-21	1996-10-21	Use of anti-embryonic hemoglobin antibodies to identify fetal cells
PCT/US1997/019447 WO1998018005A1 (fr)	1996-10-21	1997-10-20	Utilisation d'anticorps diriges contre l'hemoglobine embryonnaire pour identifier des cellules foetales

Publications (2)

Publication Number	Publication Date
IL129382A0 IL129382A0 (en)	2000-02-17
IL129382A true IL129382A (en)	2002-09-12

Family

ID=24952172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12938297A IL129382A (en)	1996-10-21	1997-10-20	Method for identifying embryonic cells using antibodies against fetal hemoglobin

Country Status (13)

Country	Link
US (1)	US5731156A (fr)
EP (1)	EP1007965B1 (fr)
JP (1)	JP4091123B2 (fr)
KR (1)	KR100523381B1 (fr)
CN (1)	CN1234117A (fr)
AT (1)	ATE290210T1 (fr)
AU (1)	AU735380B2 (fr)
BR (1)	BR9712548A (fr)
CA (1)	CA2269327A1 (fr)
DE (1)	DE69732662T2 (fr)
IL (1)	IL129382A (fr)
RU (1)	RU2178703C2 (fr)
WO (1)	WO1998018005A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6509192B1 (en) *	1992-02-24	2003-01-21	Coulter International Corp.	Quality control method
US5629147A (en) *	1992-07-17	1997-05-13	Aprogenex, Inc.	Enriching and identifying fetal cells in maternal blood for in situ hybridization
EP0864082B1 (fr) *	1995-11-30	2003-04-02	Chromavision Medical Systems, Inc.	Procede permettant d'effectuer l'analyse d'images automatisee d'echantillons biologiques
US6718053B1 (en) *	1996-11-27	2004-04-06	Chromavision Medical Systems, Inc.	Method and apparatus for automated image analysis of biological specimens
ATE308755T1 (de) *	1997-03-08	2005-11-15	Univ Dundee	Pränatale diagnostische verfahren in vitro
US5962234A (en) *	1997-10-20	1999-10-05	Applied Imaging Corporation	Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells
CA2331508A1 (fr) *	1998-05-09	1999-11-18	Ikonisys, Inc.	Procede et systeme informatises de diagnostic d'une cellule rare, y compris une cellule foetale
FR2781055B1 (fr) *	1998-07-09	2000-10-13	Immunotech Sa	Reactif et methode pour la permeabilisation et l'identification des erythrocytes
CA2413835A1 (fr) *	1999-05-25	2000-11-30	Britta Christensen	Isolation et culture de cellules embryonnaires
US6692952B1 (en) *	1999-11-10	2004-02-17	Massachusetts Institute Of Technology	Cell analysis and sorting apparatus for manipulation of cells
DE10035433C2 (de) *	2000-07-20	2002-07-18	Tuma Wolfgang	Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben
US20050214758A1 (en) *	2001-12-11	2005-09-29	Netech Inc.	Blood cell separating system
CA2500392C (fr) *	2002-09-27	2012-11-27	The General Hospital Corporation	Dispositif microfluidique pour la separation de cellules et utilisations de ce dispositif
EP1413874A1 (fr)	2002-10-16	2004-04-28	Streck Laboratories, Inc.	Méthode et appareil pour collecter et préserver des cellules pour l'analyse
US20040214243A1 (en) *	2003-04-25	2004-10-28	Beckman Coulter, Inc.	Differential determination of hemoglobins
AU2004250131A1 (en) *	2003-06-13	2004-12-29	The General Hospital Corporation	Microfluidic systems for size based removal of red blood cells and platelets from blood
AU2005218622A1 (en) *	2004-03-03	2005-09-15	Living Microsystems	Magnetic device for isolation of cells and biomolecules in a microfluidic environment
US7653260B2 (en) *	2004-06-17	2010-01-26	Carl Zeis MicroImaging GmbH	System and method of registering field of view
US8582924B2 (en) *	2004-06-30	2013-11-12	Carl Zeiss Microimaging Gmbh	Data structure of an image storage and retrieval system
ZA200701783B (en) *	2004-09-02	2009-10-28	Genentech Inc	Anti-Fc-gamma RIIB receptor antibody and uses therefor
US20070026414A1 (en) *	2005-07-29	2007-02-01	Martin Fuchs	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070196820A1 (en)	2005-04-05	2007-08-23	Ravi Kapur	Devices and methods for enrichment and alteration of cells and other particles
US20070026413A1 (en) *	2005-07-29	2007-02-01	Mehmet Toner	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026415A1 (en) *	2005-07-29	2007-02-01	Martin Fuchs	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026417A1 (en) *	2005-07-29	2007-02-01	Martin Fuchs	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090181421A1 (en) *	2005-07-29	2009-07-16	Ravi Kapur	Diagnosis of fetal abnormalities using nucleated red blood cells
US20070026416A1 (en) *	2005-07-29	2007-02-01	Martin Fuchs	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8921102B2 (en)	2005-07-29	2014-12-30	Gpb Scientific, Llc	Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070059680A1 (en) *	2005-09-15	2007-03-15	Ravi Kapur	System for cell enrichment
US20070059716A1 (en) *	2005-09-15	2007-03-15	Ulysses Balis	Methods for detecting fetal abnormality
US20070059774A1 (en) *	2005-09-15	2007-03-15	Michael Grisham	Kits for Prenatal Testing
US20070059719A1 (en) *	2005-09-15	2007-03-15	Michael Grisham	Business methods for prenatal Diagnosis
US20070059718A1 (en) *	2005-09-15	2007-03-15	Mehmet Toner	Systems and methods for enrichment of analytes
US20070059683A1 (en) *	2005-09-15	2007-03-15	Tom Barber	Veterinary diagnostic system
US20070059781A1 (en) *	2005-09-15	2007-03-15	Ravi Kapur	System for size based separation and analysis
ES2374686T3 (es)	2007-05-14	2012-02-21	Historx, Inc.	Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes.
JP5593221B2 (ja) *	2007-06-15	2014-09-17	ヒストロックス，インコーポレイテッド．	顕微鏡機器を標準化するための方法およびシステム
CA2604317C (fr)	2007-08-06	2017-02-28	Historx, Inc.	Methodes et systeme permettant de valider des echantillons d'images pour dosages immunologiques quantitatifs
CA2596204C (fr) *	2007-08-07	2019-02-26	Historx, Inc.	Procede et systeme de determination de la dilution optimale d'un reactif
WO2009029810A1 (fr) *	2007-08-31	2009-03-05	Historx, Inc.	Sélection de temps d'exposition automatique pour un tissu d'imagerie
WO2009085745A1 (fr) *	2007-12-20	2009-07-09	Cytyc Corporation	Procédé de séparation magnétique de globules rouges d'un échantillon de patient
EP2250497B1 (fr) *	2008-02-18	2014-09-10	Genetic Technologies Limited	Procedes de traitement et/ou d'enrichissement de cellules
US20100159506A1 (en) *	2008-07-25	2010-06-24	Cellscape Corporation	Methods and systems for genetic analysis of fetal nucleated red blood cells
AU2009293380B2 (en) *	2008-09-16	2016-05-19	Novartis Ag	Reproducible quantification of biomarker expression
US20100167271A1 (en) *	2008-12-30	2010-07-01	Streck, Inc.	Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) *	2009-01-21	2023-04-25	Streck Llc	Preservation of fetal nucleic acids in maternal plasma
US20100298453A1 (en) *	2009-01-26	2010-11-25	Invista North America S.A R.L.	Board stock foam having biobased content
US8231007B2 (en) *	2009-01-29	2012-07-31	Wark Rickey E	Static classifier cage
EP3290530B1 (fr)	2009-02-18	2020-09-02	Streck Inc.	Préservation d'acides nucléiques acellulaires
WO2010121294A1 (fr) *	2009-04-21	2010-10-28	Genetic Technologies Limited	Procédés d'obtention de matériel génétique foetal
US20120129183A1 (en) *	2009-06-24	2012-05-24	Rappaport Family Institute For Research In The Medical Sciences	Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
EP3103883A1 (fr) *	2009-11-09	2016-12-14	Streck, Inc.	Stabilisation de l'arn et extraction de l'arn dans des cellules intactes dans un échantillon de sang
CA2787135C (fr)	2010-01-21	2018-11-20	Biocep Ltd.	Separation magnetique de cellules rares
US8774488B2 (en)	2010-03-11	2014-07-08	Cellscape Corporation	Method and device for identification of nucleated red blood cells from a maternal blood sample
JP5822913B2 (ja) *	2010-04-20	2015-11-25	ヴェンタナメディカルシステムズ，インク．	２色発色性インサイツハイブリダイゼーション
WO2012151391A2 (fr)	2011-05-04	2012-11-08	Streck, Inc.	Compositions virales inactivées et leurs procédés de préparation
CA2869681A1 (fr) *	2011-12-23	2013-06-27	Advanced Technologies And Regenerative Medicine, Llc	Detection de cellules extraites du tissu du cordon ombilical chez l'homme
WO2013192342A1 (fr) *	2012-06-20	2013-12-27	Celula, Inc.	Matériels et procédés de traitement de populations cellulaires
WO2013192620A1 (fr)	2012-06-22	2013-12-27	Quantrx Biomedical Corporation	Procédé d'obtention de cellules fœtales et composants cellulaires fœtaux
WO2014085593A1 (fr) *	2012-11-27	2014-06-05	Children's Medical Center Corporation	Ciblage d'éléments régulateurs distaux bcl11a pour la réinduction d'hémoglobine fœtale
ES2756098T3 (es) *	2013-03-27	2020-04-27	Theranos Ip Co Llc	Métodos, dispositivos y sistemas para el análisis de muestras
ES2938048T3 (es)	2013-07-24	2023-04-04	Streck Llc	Composiciones y procedimientos para estabilizar las células tumorales circulantes
CA2984884A1 (fr) *	2014-05-15	2015-11-19	Kellbenx Incorporated	Preparation de globules rouges nucleees ftales (nrbc) pour test de diagnostic
US11168351B2 (en)	2015-03-05	2021-11-09	Streck, Inc.	Stabilization of nucleic acids in urine
CN104977284B (zh) *	2015-07-03	2018-05-29	石莹	一种胎儿有核红细胞的捕获及鉴定方法
KR101794218B1 (ko) *	2015-08-19	2017-11-07	인제대학교 산학협력단	비침습적 산전 진단을 위한 산모 혈액 내 유핵 적혈구의 농축 분리 방법
WO2017057076A1 (fr) *	2015-09-28	2017-04-06	富士フイルム株式会社	Procédé pour obtenir des érythrocytes nucléés et procédé pour identifier des érythrocytes nucléés
US20170145475A1 (en)	2015-11-20	2017-05-25	Streck, Inc.	Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (fr)	2016-07-29	2018-02-01	Streck, Inc.	Composition de suspension pour contrôle d'analyse hématologique
JP6234542B1 (ja)	2016-12-27	2017-11-22	株式会社 TL Genomics	胎児細胞由来染色体ｄｎａの取得方法
SG11202002907RA (en)	2017-10-19	2020-05-28	Tl Genomics Inc	Cell classification chip
JP7293244B2 (ja)	2017-10-19	2023-06-19	ストレック，インコーポレイテッド	溶血、凝固調節および細胞外小胞の安定化のための組成物
CN109115584A (zh) *	2018-09-10	2019-01-01	首都医科大学附属北京妇产医院	一种检测红细胞中血红蛋白f的检测试剂及其应用
US20220235420A1 (en) *	2019-07-15	2022-07-28	Menarini Biomarkers Singapore Pte Ltd	Compositions and methods for isolating, detecting, and analyzing fetal cells
CN111948404B (zh) *	2020-08-03	2023-04-07	融智生物科技（青岛）有限公司	用于筛查地中海贫血的特征蛋白标记组合物、质谱模型及其应用
CN116183469B (zh) *	2022-12-16	2025-12-02	河北明志康华生物科技有限公司	一种胎儿红细胞流式细胞检测的方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0791659A3 (fr) *	1989-11-13	1997-09-17	Children's Medical Center Corporation	Séparation antigène-spécifique des cellules foetales nuclées dans la détection noninvasif d'ADN foetale
JPH07509136A (ja) *	1992-07-17	1995-10-12	バイシス，インク．	インサイチュ（ｉｎ　ｓｉｔｕ）・ハイブリダイゼーションのための母体血液中の胎児細胞の富化と同定
US5457024A (en) *	1993-01-22	1995-10-10	Aprogenex, Inc.	Isolation of fetal erythrocytes
WO1995003431A1 (fr) *	1993-07-19	1995-02-02	Aprogenex, Inc.	Enrichissement et identification de cellules f×tales dans du sang maternel destinees a une hybridation in situ
US5580724A (en) *	1994-03-25	1996-12-03	Board Of Regents, The University Of Texas System	Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis

1996
- 1996-10-21 US US08/734,556 patent/US5731156A/en not_active Expired - Lifetime
1997
- 1997-10-20 BR BR9712548-2A patent/BR9712548A/pt not_active Application Discontinuation
- 1997-10-20 RU RU99110373/14A patent/RU2178703C2/ru not_active IP Right Cessation
- 1997-10-20 KR KR10-1999-7003439A patent/KR100523381B1/ko not_active Expired - Fee Related
- 1997-10-20 AU AU49200/97A patent/AU735380B2/en not_active Ceased
- 1997-10-20 IL IL12938297A patent/IL129382A/en not_active IP Right Cessation
- 1997-10-20 AT AT97911938T patent/ATE290210T1/de not_active IP Right Cessation
- 1997-10-20 WO PCT/US1997/019447 patent/WO1998018005A1/fr not_active Ceased
- 1997-10-20 DE DE69732662T patent/DE69732662T2/de not_active Expired - Fee Related
- 1997-10-20 EP EP97911938A patent/EP1007965B1/fr not_active Expired - Lifetime
- 1997-10-20 CN CN97199005A patent/CN1234117A/zh active Pending
- 1997-10-20 CA CA002269327A patent/CA2269327A1/fr not_active Abandoned
- 1997-10-20 JP JP51969498A patent/JP4091123B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU735380B2 (en)	2001-07-05
AU4920097A (en)	1998-05-15
HK1031255A1 (en)	2001-06-08
CA2269327A1 (fr)	1998-04-30
EP1007965A4 (fr)	2000-06-14
DE69732662T2 (de)	2005-12-29
RU2178703C2 (ru)	2002-01-27
WO1998018005A1 (fr)	1998-04-30
IL129382A0 (en)	2000-02-17
BR9712548A (pt)	1999-12-21
JP2001502805A (ja)	2001-02-27
EP1007965B1 (fr)	2005-03-02
KR100523381B1 (ko)	2005-10-24
US5731156A (en)	1998-03-24
JP4091123B2 (ja)	2008-05-28
DE69732662D1 (de)	2005-04-07
CN1234117A (zh)	1999-11-03
KR20000052662A (ko)	2000-08-25
ATE290210T1 (de)	2005-03-15
EP1007965A1 (fr)	2000-06-14

Publication	Publication Date	Title
AU735380B2 (en)	2001-07-05	Use of anti-embryonic hemoglobin antibodies to identify fetal cells
US5962234A (en)	1999-10-05	Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells
CA2140278C (fr)	2009-03-17	Enrichissement et determination des cellules foetales dans le sang maternel pour hybridation in situ
US5714325A (en)	1998-02-03	Prenatal diagnosis by isolation of fetal granulocytes from maternal blood
US5153117A (en)	1992-10-06	Fetal cell recovery method
EP0500727B1 (fr)	1998-01-21	Procede non envahissant d'isolation et de detection d'adn f tal
US6210889B1 (en)	2001-04-03	Method for enrichment of fetal cells from maternal blood and use of same in determination of fetal sex and detection of chromosomal abnormalities
US5861311A (en)	1999-01-19	Preserved, non-infectious control cells prepared by the modulation or modification of normal leukocytes
Davis et al.	1995	Use of monoclonal antibodies and flow cytometry to cluster and analyze leukocyte differentiation molecules
JPH09510875A (ja)	1997-11-04	母親の末梢血からの胎児細胞の培養および単離
WO1994025873A1 (fr)	1994-11-10	Procedes d'enrichissement de cellules souches f×tales provenant du sang maternel
EP0660664B1 (fr)	2002-04-17	Cellules temoins conservees et non infectieuses utilisees pour identifier une maladie par analyse de sang
Christensen et al.	2003	Studies on the isolation and identification of fetal nucleated red blood cells in the circulation of pregnant women before and after chorion villus sampling
US5763204A (en)	1998-06-09	Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing
HK1031255B (en)	2006-01-27	Use of anti-embryonic hemoglobin antibodies to identify fetal cells
MXPA99003697A (en)	2000-06-01	Use of anti-embryonic hemoglobin antibodies to identify fetal cells
US4693967A (en)	1987-09-15	Monitoring therapy results in body samples of receptor cells
Bischoff et al.	2002	Prenatal Diagnosis of Chromosomal Abnormalities Using Maternal Blood
AU9718698A (en)	1999-03-04	Prenatal diagnosis by isolation of fetal granulocytes from maternal blood
AU7735201A (en)	2003-04-03	Fetal cell recovery method

Legal Events

Date	Code	Title
2003-02-12	FF	Patent granted
2003-05-29	KB	Patent renewed
2004-01-04	KB	Patent renewed
2008-01-06	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees